Statistical analyses were performed using SPSS (Chicago, IL). Sensitivity, specificity, positive predictive value (PPV), and negative predictive ALK inhibitor value (NPV) were also calculated to determine the reliability of predictors of the response to therapy. Sustained virological response was achieved by 44 of 72 (61.1%) patients.

In all, 64 of 72 (88.9%) patients were considered end-of-treatment response. According to treatment regimen, sustained virological response were achieved by 45.0% (9 of 20 patients) and 67.3% (35 of 52 patients), in the T12PR12 group and the T12PR24 group, respectively. Of eight patients who could not achieve end-of-treatment response, six (75.0%) patients resulted in reelevation of viral loads regardless of HCV-RNA temporary negative, and the other two patients (25.0%) did not achieve HCV-RNA negative during treatment. Especially in the T12PR24 group, according to the past history of treatment, sustained

virological response were achieved by 76.4% (13 of 17 patients), 86.4% (19 of 22 patients), and 23.1% (3 of 13 patients), in treatment-naive, relapsers to previous treatment, and nonresponders to previous treatment, respectively. According to the substitution of core aa 70, a significantly higher proportion of patients with Arg70 substitutions (74.4%) showed sustained virological www.selleckchem.com/products/ulixertinib-bvd-523-vrt752271.html response than that of patients who showed Gln70(His70) (41.4%) (Fig.

1, P = 0.007). In contrast, according to the substitution of core aa 91, the sustained virological response rate was not significantly different between Leu91 (65.0%) and Met91 (56.3%) (Fig. 1). Likewise, according to the numbers of aa substitutions in ISDR, the sustained virological response rate was not significantly different between wildtype (56.3%) and nonwildtype (66.7%) (Fig. 1). Thus, sustained MCE virological response was influenced by the substitution of core aa 70. According to the genetic variation in rs8099917, sustained virological response was achieved by 83.8% (31 of 37 patients), 29.6% (8 of 27 patients), and 0% (0 of 2 patients) in patients with genotype TT, TG, and GG, respectively. Thus, a significantly higher proportion of patients with genotype TT (83.8%) showed sustained virological response than that of patients who showed genotype non-TT (27.6%) (Fig. 2, P < 0.001) (Table 2). According to the genetic variation in rs12979860, sustained virological response was achieved by 83.8% (31 of 37 patients), 34.5% (10 of 29 patients), and 0% (0 of 2 patients), in patients with genotype CC, CT, and TT, respectively. Thus, a significantly higher proportion of patients with genotype CC (83.